ClinicalTrials.gg
RecruitingNCT07941856Updated Nov 17, 2026

A Mixed-Method Study for Implementation of Central Line-Associated Bloodstream Infection Control in Intensive Care Units

An interventional study of Central-line-associated bloodstream infection prevention bundle in Catheter-Related Bloodstream Infection and Healthcare-Associated Infection, sponsored by Peking University First Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Peking University First Hospital · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Nov 2024, registered Sep 2026).
  • Started Nov 2024; still recruiting 2 years later.
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,200
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Cross Infection with a site in China — 3 open to participants now, 4 under way, none of them phase 3. Cross Infection · China.

Started
2024
the only one that year
No phase
7 of 11
3 open now
Registered
11th of 11
by date
Lead sponsor
1 of 11
Peking University First Hospital

Among the 11 studies in Cross Infection with a site in China, this one is the only one that started in 2024, is one of 7 with no phase, and was the 11th registered.

Cross Infection

286 studies on the registry are indexed under Cross Infection; 48 are open to participants now.

Browse Cross Infection studies →

Open to participants now

3 of the 11 studies in Cross Infection with a site in China are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 27 Cross Infection studies recruiting now, 22 (81%) set no upper age limit and 3 (11%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Cross Infection with a site in China, or all of them as a file.
02

Study summary

This is a phased mixed-method implementation study aiming to develop and evaluate a multi-component central-line-associated bloodstream infection (CLABSI) prevention bundle in three intensive-care units (Respiratory Intensive Care Unit, RICU; Surgical Intensive Care Unit, SICU; Neonatal Intensive Care Unit, NICU) at Peking University First Hospital. This study will first conduct pilot testing of the refined bundle in NICU, then scale-up implementation across all three ICUs. CLABSI incidence rate per 1000 central line-days is the primary outcome; bundle adherence rate and multi-dimensional implementation outcomes are secondary outcomes.

03

Conditions studied

  • Catheter-Related Bloodstream Infection
  • Healthcare-Associated Infection

Browse trials for

Keywords

  • Central-line-associated bloodstream infection
  • Infection control
  • Intensive Care Unit
  • Implementation science
  • Quality improvement
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Admitted to RICU, SICU or NICU of Peking University First Hospital during study period
  2. Has an indwelling central venous catheter (CVC, non-tunneled), peripherally inserted central catheter (PICC), or umbilical venous catheter (UVC)
  3. Generates central-line-days within study observation window

Exclusion criteria

Exclusion Criteria:

  1. CVC placed in external hospitals and not managed within the three participating ICUs
  2. Central-line-days generated outside study observation period
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,200 participants (estimated)

Study arms

  • Experimental
    CLABSI Prevention Bundle Intervention Arm

    Single-group intervention, implementing multi-component CLABSI prevention bundle in NICU, RICU and SICU with phased roll-out

    Behavioral: Central-line-associated bloodstream infection prevention bundle

Interventions

  • BehavioralCentral-line-associated bloodstream infection prevention bundle

    A multi-component CLABSI prevention bundle with six core measures: (1) preferable insertion site selection, (2) hand hygiene, (3) maximum sterile barrier precautions, (4) catheter hub disinfection and insertion site care, (5) timely removal of non-essential catheters, and (6) implementation of a standardized checklist. The study adopts a phased implementation design: a pilot phase will first be conducted in NICU to test the bundle, identify implementation barriers, and refine local strategies; after optimization, the refined bundle will be rolled out across RICU, SICU and NICU. Local implementation teams will develop tailored action plans, monitor adherence, and iteratively optimize implementation strategies throughout the study.

06

What researchers measure

Primary outcomes

  1. CLABSI incidence rate

    CLABSI cases per 1000 central-line-days, defined according to Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN) criteria. Calculated as number of CLABSI events divided by total central-line-days multiplied by 1000, collected prospectively in RICU, SICU and NICU.

    Time frame: Baseline through intervention period, up to 36 months

Secondary outcomes

  1. Overall CLABSI prevention bundle adherence score

    A composite adherence score calculated as the mean proportion of correctly performed elements across six core CLABSI-prevention bundle measures (hand hygiene, maximum sterile barrier precautions, preferable insertion site, disinfection and site care, nonessential catheter removal, and checklist completion), assessed by direct observation and chart review. The score is expressed as a single percentage ranging from 0% to 100%.

    Time frame: Baseline through implementation period, up to 36 months

  2. Acceptability of the CLABSI prevention intervention bundle

    Acceptability will be assessed through semi-structured interviews with healthcare professionals involved in implementation to explore perceptions of whether the intervention bundle is agreeable and satisfactory in routine clinical practice. Findings will be reported as qualitative themes and categories.

    Time frame: Entire study duration, up to 36 months

  3. Fidelity of implementation of the intervention bundle - Quantitative assessment

    The degree to which the intervention bundle is implemented as intended according to predefined implementation procedures, assessed by quantitative process indicators, case audits, and checklists. Fidelity will be reported as the proportion of predefined procedures correctly completed.

    Time frame: Entire study duration, up to 36 months

  4. Fidelity of implementation of the intervention bundle - Qualitative assessment

    The degree to which the intervention bundle is implemented as intended, assessed through semi-structured interviews with implementation stakeholders. Qualitative findings regarding barriers and facilitators to implementation fidelity will be reported as themes.

    Time frame: Entire study duration, up to 36 months

  5. Feasibility of implementation of the intervention bundle

    Feasibility will be assessed through semi-structured interviews with healthcare professionals to determine the extent to which the intervention bundle can be successfully implemented within participating intensive care units. Findings will be reported as qualitative themes describing barriers and facilitators to implementation.

    Time frame: Entire study duration, up to 36 months

  6. Sustainability of implementation of the intervention bundle - Quantitative assessment

    The extent to which implementation of the intervention bundle is maintained over time, assessed using quantitative process indicators. Sustainability will be reported as the proportion of bundle elements continued in routine clinical practice.

    Time frame: Entire study duration, up to 36 months

  7. Sustainability of implementation of the intervention bundle - Qualitative assessment

    The extent to which implementation of the intervention bundle is integrated into routine clinical practice over time, assessed through semi-structured interviews. Qualitative findings will be reported as themes.

    Time frame: Entire study duration, up to 36 months

07

Study locations

1 of 1 sites recruiting
  • Peking University First Hospital
    Beijing, Beijing Municipality 100034, China
    Recruiting
    • Shuo Li, M.D. · Contactshuoli_bjmu@126.com · +86-13671275323
    • Xi Yao, MMSc · Contactyaoxi@pku.edu.cn · +86-13811429675
    • Liuyi Li, MMSc · Principal investigator
    • Hongling Chu, Ph.D. · Principal investigator
    • Xi Yao, MMSc · Principal investigator
    • Meihua Hu, MMSc · Sub investigator
    • Yuan Cheng, M.D. · Sub investigator
    • Tian Sang, M.D. · Sub investigator
    • Cui Yuan, MMSc · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — Individual-participant data will not be shared publicly because of patient privacy restrictions and local institutional data security requirements. Aggregated study results may be published in peer-reviewed journals.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Dec 2026, 25 months after the start.

Of 58 non-industry interventional studies with no phase under Cross Infection, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's planned 25 months is above that.

Counting every sponsor, half of 60 studies reached it within 16 months; a quarter within 7 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Nov 17, 2026
StartActual
Nov 1, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941856
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Nov 1, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 17, 2026

Study contacts

Shuo Li, M.D.
Contact
shuoli_bjmu@126.com
+86-13671275323
Xi Yao, MMSc
Contact
yaoxi@pku.edu.cn
+86-13811429675
Shuo Li, M.D.
principal investigator · Peking University First Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion